Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 1, Janvier 2004
Page(s) 45 - 53
Section M/S revues
Publié en ligne 15 janvier 2004
  1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner T. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346 : 561–4. [Google Scholar]
  2. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258 : 1946–9. [Google Scholar]
  3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365 : 61–5. [Google Scholar]
  4. Fride E. Endocannabinoids in the central nervous system-an overview. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 221–33. [Google Scholar]
  5. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in the brain that bind to the cannabinoid receptor. J Med Chem 1993; 36 : 3032–4. [Google Scholar]
  6. Mechoulam R, Ben-Shabat S, Hanus L, et al. identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50 : 83–90. [Google Scholar]
  7. Hanus L, Abu-Lafi S, Fride E, et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98 : 3662–5. [Google Scholar]
  8. Giuffrida R, Beltramo M, Piomelli D. Mechanism of endocannabinoid inactivation : biochemistry and pharmacology. J Pharm Exp Ther 2001; 298 : 7–14. [Google Scholar]
  9. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 101–21. [Google Scholar]
  10. Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C. In cultured mouse astrocytes, but not in neurons, anandamide has pharmacological effects distincts from synthetic cannabinoids. Eur J Neurosci 1999; 11 : 691–9. [Google Scholar]
  11. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptors on anxiety. Eur J Neurosci 2002; 16 : 395–8. [Google Scholar]
  12. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 377–91. [Google Scholar]
  13. Suguira T, Koyabashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 173–92. [Google Scholar]
  14. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58 : 315–48. [Google Scholar]
  15. McAllister SD, Glass M. CB1 and CB2 receptor-mediated signalling : a focus on endocannabinoids. Prostaglandins, Leukotrienes and Essential Fatty Acids 2002; 66 : 161–71. [Google Scholar]
  16. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. Embo J 2001; 20 : 7033–40. [Google Scholar]
  17. Maingret F, Patel AJ, Lazdunski M, Honore E. The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK-1. Embo J 2001; 20 : 47–54. [Google Scholar]
  18. Schweitzer P. Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J Neurosci 2000; 20 : 51–8. [Google Scholar]
  19. Venance L, Piomelli D, Glowinski J, Giaume C. Inhibition by anadamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 1995; 376 : 590–4. [Google Scholar]
  20. Venance L, Sagan S, Giaume C. R-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes. Eur J Physiol 1997; 434 : 147–9. [Google Scholar]
  21. Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids : involvement of sustained ceramide accumulation and extracellular signal-regulated kinase regulation. Nat Med 2000; 6 : 313–9. [Google Scholar]
  22. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002; 95 : 175–84. [Google Scholar]
  23. Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci 2002; 5 : 723–4. [Google Scholar]
  24. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296 : 678–82. [Google Scholar]
  25. Kreitzer AC, Regehr WG. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol 2002; 12 : 324–30. [Google Scholar]
  26. Llano I, Leresche N, Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 1991; 6 : 565–74. [Google Scholar]
  27. Pitler TA, Alger BE. Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci 1992; 12 : 4122–32. [Google Scholar]
  28. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001; 21 : 109–16. [Google Scholar]
  29. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002; 99 : 8384–8. [Google Scholar]
  30. Doherty J, Dingledine R. Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. Curr Opin Pharmacol 2003; 3 : 46–53. [Google Scholar]
  31. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 2002; 5 : 446–51. [Google Scholar]
  32. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418 : 530–4. [Google Scholar]
  33. Costa B, Vailati S, Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 1999; 10 : 327–31. [Google Scholar]
  34. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38 : 151–78. [Google Scholar]
  35. Ledent C, Valverde O, Cossu G, et al. Unresponsivenes to cannabinoids and feduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283 : 15. [Google Scholar]
  36. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63 : 569–611. [Google Scholar]
  37. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 1998; 286 : 1301–8. [Google Scholar]
  38. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394 : 277–281. [Google Scholar]
  39. Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 1999; 19 : 6795–805. [Google Scholar]
  40. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388 : 773–8. [Google Scholar]
  41. Reibaud M, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 1999; 379 : R1-R2 [Google Scholar]
  42. Murillo-Rodriguez E, Sanchez-Alavez M, Navarro L, Martinez-Gonzalez D, Drucker-Colin R, Prospero-Garcia O. Anandamide modulates sleep and memory in rats. Brain Res 1998; 812 : 270–4. [Google Scholar]
  43. Chakrabarti A, Ekuta JE, Onaivi ES. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain Res Bull 1998; 45 : 67–74 [Google Scholar]
  44. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol. Psychopharmacology 2002; 163 : 111–7. [Google Scholar]
  45. Miczek KA. Delta9-tetrahydrocannabinol : Antiagressive effects in mice, rats, and squirrel monkeys. Science 1978; 199 : 1459–61. [Google Scholar]
  46. Rodriguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414 : 209–12. [Google Scholar]
  47. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95 : 127–35. [Google Scholar]
  48. Hamann W, di Vadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet 1999; 353 : 560. [Google Scholar]
  49. Jarvinen T, Pate DW, Laine K. Cannabinoids in the treatment of glaucoma. Pharmacol Ther 2002; 95 : 203–20. [Google Scholar]
  50. Berry EM, Mechoulam R. Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther 2002; 95 : 185–90. [Google Scholar]
  51. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21 : 218–24. [Google Scholar]
  52. Romero J, Lastres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002; 95 : 137–52. [Google Scholar]
  53. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95 : 165–74. [Google Scholar]
  54. Van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002; 26 : 317–46. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.